Investor says biotech is languishing in the UK

A leading biotech investor in the U.K. says that the London market just doesn't "get it" about drug developers. And the disconnect has led to the smallest number of biotech start-ups in years. Only 37 biotech companies started up last year in the U.K., the smallest number since 1999. Sir Chris Evans, who founded Merlin Biosciences, told The Independent that U.S. biotechs, meanwhile, are making swift strides in a much more entrepreneurial environment.

"U.S. biotech teams are vastly more creative and entrepreneurial by comparison," said Evans. "They can recognize huge value potential in projects when the U.K. often sees little."

- read the report from The Independent

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.